| Paradigms on immunotherapy combinations with chemotherapy D Salas-Benito, JL Pérez-Gracia, M Ponz-Sarvisé, ME Rodriguez-Ruiz, ... Cancer discovery 11 (6), 1353-1367, 2021 | 229 | 2021 |
| Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy SM Fernandez-Poma, D Salas-Benito, T Lozano, N Casares, JI Riezu-Boj, ... Cancer research 77 (13), 3672-3684, 2017 | 117 | 2017 |
| Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value E Alegre, JP Fusco, P Restituto, D Salas-Benito, ME Rodriguez-Ruiz, ... Tumor Biology 37, 13687-13694, 2016 | 43 | 2016 |
| Inflammation and immunity in ovarian cancer D Salas-Benito, E Vercher, E Conde, J Glez-Vaz, I Tamayo, ... European Journal of Cancer Supplements 15, 56-66, 2020 | 19 | 2020 |
| The BRCA gene in epithelial ovarian cancer L Sánchez-Lorenzo, D Salas-Benito, J Villamayor, A Patiño-García, ... Cancers 14 (5), 1235, 2022 | 18 | 2022 |
| The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating … D Salas-Benito, E Conde, I Tamayo-Uria, U Mancheño, E Elizalde, ... British journal of cancer 124 (6), 1138-1149, 2021 | 18 | 2021 |
| Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov 2021; 11: 1353–67. doi: 10.1158/2159-8290 D Salas-Benito, JL Pérez-Gracia, M Ponz-Sarvisé, ME Rodriguez-Ruiz, ... CD-20-1312, 0 | 9 | |
| Vaccination for pancreatic ductal adenocarcinoma: a hard nut to crack D Salas-Benito, I Melero, M Ponz-Sarvise Clinical Cancer Research 25 (18), 5435-5437, 2019 | 7 | 2019 |
| Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. 2021; 11 (6): 1353–1367. doi: 10.1158/2159-8290 D Salas-Benito, JL Pérez-Gracia, M Ponz-Sarvisé, ME Rodriguez-Ruiz, ... CD-20-1312.[Abstract][CrossRef][Google Scholar], 0 | 7 | |
| Hurdles race for CAR T‐cell therapy in digestive tract cancer MN Kronig, M Wehrli, D Salas‐Benito, MV Maus Immunological reviews 320 (1), 100-119, 2023 | 5 | 2023 |
| Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. 2021; 11 (6): 1353–67 D Salas-Benito, JL Perez-Gracia, M Ponz-Sarvise, ME Rodriguez-Ruiz, ... | 5 | |
| Senescent T cells as a resistance mechanism to lung cancer immunotherapy D Salas-Benito, I Eguren-Santamaria, MF Sanmamed Clinical Cancer Research 27 (2), 374-376, 2021 | 4 | 2021 |
| Single-institution experience in clinical trials during the COVID-19 pandemic in Spain: not so bad after all? P Rodriguez-Otero, J Reis, A Alfonso-Pierola, D Salas-Benito, M Giraldez, ... JCO Global Oncology 6, 2020 | 3 | 2020 |
| Genetic retargeting of E3 ligases to enhance CAR T cell therapy IC Lane, G Kembuan, J Carreiro, MC Kann, W Lin, AA Bouffard, J Kreuzer, ... Cell Chemical Biology 31 (2), 338-348. e5, 2024 | 2 | 2024 |
| Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies D Salas-Benito, TR Berger, MV Maus Annual Review of Cancer Biology 7, 23-42, 2023 | 2 | 2023 |
| Pre-selection of PD-1+ tumor-infiltrating CD8+ T cells improves the efficacy of adoptive T-cell therapy D Salas-Benito, N Casares, P Sarobe, JJ Lasarte, S Hervas-Stubbs Journal of Immunological Sciences 2 (1), 2018 | 2 | 2018 |
| Chimeric antigen receptor (CAR) T cells overexpressing Bcl-xL increase proliferation and antitumor activity alone and in combination with BH3 mimetics F Korell, M Olson, D Salas-Benito, MB Leick, RC Larson, H Silva, ... Cancer Research 83 (7_Supplement), 4098-4098, 2023 | 1 | 2023 |
| The mutational load and a T-cell inflamed tumor phenotype identify ovarian cancer patients rendering tumor-reactive T cells from PD-1+ tumor-infiltrating lymphocytes D Salas-Benito, E Conde, I Tamayo-Uria, U Mancheño, E Elizalde, ... | 1 | 2020 |
| Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma M Wehrli, S Guinn, F Birocchi, A Kuo, Y Sun, RC Larson, AJ Almazan, ... Clinical Cancer Research 30 (9), 1859-1877, 2024 | | 2024 |
| Tandem CAR-T cells against mesothelin and MUC16ectoto overcome tumor-antigen heterogenicity D Salas-Benito, F Birocchi, A Armstrong, AA Bouffard, T Kienka, F Korell, ... Cancer Research 84 (6_Supplement), 3992-3992, 2024 | | 2024 |
